Highest-materiality recent filing
Cingulate joins Russell 3000E Index; CMO trial period extended to Sept 30
Added to Russell 3000E Index, effective after June 2026 reconstitution; semi-annual reconstitution begins Dec 2026.
Cingulate receives first US patent for ADHD drug CTx-1301 through Dec 2042
USPTO issued Patent No. 12,653,791 covering CTx-1301 formulation and method of use through Dec 2042.
Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only
FDA issued a Complete Response Letter for CTx-1301 (dexmethylphenidate HCl) NDA for ADHD.
Cingulate board reduces size; two directors not seeking re-election; Hargroves changes class
Class II directors Jeff Ervin and Jay Roberts will not stand for re-election at 2026 Annual Meeting.
Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31
Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.
Cingulate appoints Frederick Jiang to Board; grants 15,000-share option
Zhanpeng 'Frederick' Jiang appointed Class I director effective March 27, 2026.
Cingulate enters $100M at-the-market equity facility with A.G.P.
Entered ATM Sales Agreement with A.G.P./Alliance Global Partners for up to $100M gross proceeds.
Cingulate reports $22.4M FY2025 net loss, CTx-1301 patent allowed, PDUFA May 2026
Net loss of $22.4M for 2025 vs $16.6M in 2024; Q4 net loss $6.3M.
Cingulate closes $12M PIPE financing, appoints Jeff Hargroves to board and converts debt
Cingulate completed $12M private placement led by Falcon Creek Capital at $5.04 per share with 80% warrant coverage
Cingulate closes $6.5M private placement tranche; issues shares for debt
Completed portion of private placement for gross proceeds of $6.5M on Feb 6, 2026; remaining $5.5M expected to close soon.
Cingulate raises ~$12M in private placement of common stock, preferred, and warrants
Gross proceeds ~$12M; issues 2.15M common shares, 973 shares Series A preferred at $1,000 stated value, and warrants for 1.87M shares.
Cingulate ups ATM offering by $8.4M to $31.94M, files new prospectus supplement
Maximum aggregate offering price increased from $23,536,658 to $31,936,658 under ATM with H.C. Wainwright.
Cingulate issues 426,853 shares to lenders through debt conversion from Nov 21 to Jan 2
Issued shares in six tranches between Nov 21, 2025 and Jan 2, 2026 to settle debt.
CEO Shane Schaffer reinstated after no-contest plea; amended employment agreement modified severance
Shane Schaffer reinstated as CEO Dec 15, 2025, after administrative leave; pled no contest to misdemeanor, received 12 months probation.
Cingulate Q3 net loss $7.3M widens 78% YoY; NDA for CTx-1301 accepted with PDUFA May 31, 2026
Net loss $7.3M vs $4.1M in Q3 2024; operating loss $6.0M on R&D $2.8M (+99.5% YoY) and G&A $3.1M (+69.7%).
Cingulate completes $6M debt financing, appoints Bryan Downey as CCO
Issued $6.57M unsecured promissory note at 9% interest, maturing 18 months, to Avondale Capital for $6M net proceeds.
FDA accepts Cingulate's NDA for CTx-1301 in ADHD; PDUFA date May 31, 2026
FDA accepted NDA for CTx-1301 (dexmethylphenidate), a once-daily PTR stimulant for ADHD in children and adults, under 505(b)(2) pathway.
Cingulate shareholders approve issuance of >20% stock to Lincoln Park Capital
Approved issuance of >20% of common stock to Lincoln Park Capital Fund, LLC under purchase agreement.
Cingulate issues 325,729 shares to lenders in debt-for-equity swaps
July 30: 58,139 shares at $5.16 per share issued to lender for debt reduction.
John A. Roberts appointed Executive Chairman effective Aug 14; receives $10,000/month cash retainer.
Cingulate Q2 net loss widens to $4.8M; files NDA for CTx-1301 with FDA
Net loss of $4.8M in Q2 2025, up from $3.2M in Q2 2024; R&D spend +43.6% to $2.7M.
CEO Shane Schaffer charged with one count of aggravated domestic battery on August 9, 2025.
Cingulate terminates EVP/COO Laurie A. Myers on August 7, 2025
Laurie A. Myers, Executive Vice President and Chief Operating Officer, terminated.
Cingulate submits NDA to FDA for lead ADHD drug CTx-1301
Submitted NDA on July 31, 2025 for CTx-1301 (dexmethylphenidate) for ADHD.
Cingulate issues 144,063 common shares and 30,000 option in unregistered sales from Mar 31 to Jul 21
Issued 7,538 shares at $4.36/share to a service provider on May 12, 2025.
Cingulate enters $25M equity purchase agreement with Lincoln Park Capital
Lincoln Park Capital commits to buy up to $25M of Cingulate common stock over 36 months, starting after SEC registration effective.
Stockholders authorized a reverse stock split at a ratio between 1:2 and 1:25, to be determined by board before June 10, 2026.
Cingulate terminates grant agreement for CTx-2103; no funds received
Terminated Grant Agreement with private family foundation on May 13, 2025, originally signed April 8, 2025.
Cingulate Q1 net loss $3.8M, cash $9.5M; NDA submission for CTx-1301 on track mid-2025
Net loss of $3.8M ($1.04 per share) for Q1 2025, compared to $3.0M in Q1 2024.
Cingulate receives $3M grant from private foundation to accelerate CTx-2103 (buspirone) development
Grant of $3M in three $1M tranches; first payment May 1, 2025, others upon formulation and development milestones.
Cash and equivalents $12.2M (vs $52k Dec 2023); working capital improved to $7.5M from -$9.6M.
No serious treatment-emergent adverse events, deaths, or clinically relevant trends in two pediatric Phase 3 studies and one food-effect study.
Cingulate announces dismissal of charge against CEO Shane Schaffer
Charge against CEO Shane Schaffer dismissed on January 28, 2025; matter resolved.
Cingulate amends CMO Brams' employment: salary set at $165k, quarterly equity grants eliminated
Annual base salary set at $165,000, representing part-time (50% FTE) basis.
Completed food effect study for CTx-1301 (dexmethylphenidate) in 26 healthy adults using 50mg dose.
Cingulate raises $5M via 9% promissory note; cash runway into Q4 2025, NDA target mid-2025
Net proceeds of $5.0M from $5.48M unsecured note (9% interest, 18-month maturity, $450K OID).
Cingulate posts narrower Q3 loss, cash jumps to $10M as it advances ADHD drug toward mid-2025 NDA
Net loss $3.2M vs $6.0M in Q3 2023; R&D expenses fell $2.5M to $1.4M.
Cingulate increases ATM offering capacity by $8.34M to $23.54M
Maximum aggregate offering price under ATM raised from $15,196,658 to $23,536,658.
Cingulate raises $11.7M, extends cash runway through Q2 2025; NDA for CTx-1301 targeted mid-2025
Raised approximately $11.7 million in capital during August and September 2024.
Cingulate CEO Shane Schaffer charged with aggravated domestic battery; board reaffirms support
CEO Shane Schaffer charged with one count of aggravated domestic battery on September 23, 2024.
Cingulate starts final FDA-required study for lead ADHD asset CTx-1301; raises $10M+
Commenced final FDA-required food effect study for CTx-1301 (dexmethylphenidate) for ADHD; data readout expected by end of 2024.
Cingulate regains Nasdaq minimum bid price compliance; panel monitor through May 2025
Formally notified on September 9, 2024 of regained compliance with $1.00 minimum bid price requirement.
Cingulate ups ATM offering capacity by $3.87M to $15.2M
Increased max aggregate offering price under ATM agreement from $11.33M to $15.20M.
Cingulate reports 2,179,755 shares outstanding as of Aug 28, 2024 after equity sales
As of Aug 28, 2024, common shares outstanding were 2,179,755.
Cingulate shareholders approve warrant issuance exceeding 20% of outstanding stock
Special meeting on August 28, 2024: 2,277,270 for, 189,572 against, 118,269 abstain.
Cingulate increases ATM offering capacity by $2.86M; receives European patent for ADHD drug CTx-1301
Increased maximum aggregate offering of common stock under Sales Agreement from $8.47M to $11.33M; filed prospectus supplement for $2.86M in additional shares.
Cingulate Q2 net loss narrows to $3.2M; FDA clears NDA filing for ADHD drug CTx-1301
Net loss of $3.2M in Q2 2024 vs $6.6M in Q2 2023; R&D expenses fell to $1.9M from $4.5M YoY.
Cingulate approves 1-for-12 reverse stock split to meet Nasdaq bid price requirement
Nasdaq panel granted bid price exception through Aug 23, 2024, requiring reverse split by Aug 9 and $1 close for 10 days.
Cingulate shareholders approve reverse stock split at ratio up to 1:15
Reverse split approved with 3,458,756 votes for, 885,007 against, 28,939 abstain.
Cingulate announces warrant exercise for $1.86M gross proceeds; new Series C/D warrants issued
Immediate cash exercise of Series A (2.125M shares) and Series B (1.0625M shares) warrants at reduced price $0.585/share (was $2.00).
Jeff Ervin and Jay Roberts, will not seek re-election when their respective terms expire at the Company’s 2026 Annual Meeting of Stockholders
Jeff Hargroves has agreed to resign from the Board as a Class I director solely for the purpose of being re-appointed to the Board as a Class II director.
Jeff Ervin and Jay Roberts, will not seek re-election when their respective terms expire at the Company’s 2026 Annual Meeting of Stockholders
Effective February 12, 2024, the Board of Directors (the “Board”) of Cingulate Inc. (the “Company”) fixed the number of directors constituting the Board at five directors and appointed: Bryan Lawrence, 58, as a Class III director to serve until the Company’s 2024 annual meeting of stockholders, and each of Jeffrey S. Ervin, 46, and John A. Roberts, 65, as a Class II director to serve until the Company’s 2026 annual meeting of stockholders.
Effective February 12, 2024, the Board of Directors (the “Board”) of Cingulate Inc. (the “Company”) fixed the number of directors constituting the Board at five directors and appointed: Bryan Lawrence, 58, as a Class III director to serve until the Company’s 2024 annual meeting of stockholders, and each of Jeffrey S. Ervin, 46, and John A. Roberts, 65, as a Class II director to serve until the Company’s 2026 annual meeting of stockholders.
Effective February 12, 2024, the Board of Directors (the “Board”) of Cingulate Inc. (the “Company”) fixed the number of directors constituting the Board at five directors and appointed: Bryan Lawrence, 58, as a Class III director to serve until the Company’s 2024 annual meeting of stockholders, and each of Jeffrey S. Ervin, 46, and John A. Roberts, 65, as a Class II director to serve until the Company’s 2026 annual meeting of stockholders.
On January 25, 2024, the Company appointed Jennifer L. Callahan as the Company’s Senior Vice President and Chief Financial Officer, effective immediately.
On December 12, 2023, Craig S. Gilgallon, General Counsel, informed Cingulate Inc. (the “Company”) that he was resigning as an officer of the Company and was terminating employment with Cingulate Therapeutics LLC, a wholly-owned subsidiary of the Company, effective on December 15, 2023.
On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
On December 12, 2023, Patrick Gallagher provided the Company with notice of his resignation from the Board of Directors.
On December 13, 2023, Louis G. Van Horn, Chief Financial Officer, retired from the Company, effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material